Answers are grounded in this paper and cite their sources.
A prospective, randomized study was conducted on patients of severe sepsis using ulinastatin for treatment. Total of 50 patients were taken up for this study who were randomly assigned in two groups: 25 patients in group A who were given ulinastatin and 25 patients in group B who were given placebo. Patients were evaluated clinically using Acute physiology and chronic health evaluation(APACHE), Multiple organ failure (MOF) and Glasgow coma score (GCS), at the time of admission and after therapy on the 3 rd , 8 th and 28 th day. RESULTS: There was a significant difference between the two groups regarding the organ failure scores. Patients in group A showed a better performance in APACHE II, MOF and GCS as compared to patients in group B on 3 rd , 8 th and 28 th day of admission. CONCLUSION: Ulinastatin has a beneficial role in the treatment of patients with severe sepsis.
No takes yet. Share an insight, caveat, or question.
Bashir et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: